Difference between revisions of "Low-grade glioma, pediatric"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
||
Line 32: | Line 32: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ Ater et al. 2012 (COG A9952)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ Ater et al. 2012 (COG A9952)] | ||
|1997-2005 | |1997-2005 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Stub#TPCV|TPCV]] | |[[Stub#TPCV|TPCV]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of EFS/OS | | style="background-color:#ffffbf" |Did not meet primary endpoints of EFS/OS | ||
Line 59: | Line 59: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ Gnekow et al. 2017 (SIOP-LCG 2004)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ Gnekow et al. 2017 (SIOP-LCG 2004)] | ||
|2004-2012 | |2004-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Stub#VCE|VCE]] | |[[Stub#VCE|VCE]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS |
Revision as of 02:03, 16 December 2021
Section editor transclusions This page contains studies that are specific to pediatric populations. For the more general low-grade glioma category page, follow this link.
7 regimens on this page
11 variants on this page
|
Adjuvant therapy
Carboplatin & Vincristine
back to top |
CV: Carboplatin & Vincristine
VC: Vincristine & Carboplatin
Regimen variant #1, 175/1.5 (capped vincristine)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Packer et al. 1993 | NR | Non-randomized | ||
Ater et al. 2012 (COG A9952) | 1997-2005 | Phase 3 (C) | TPCV | Did not meet primary endpoints of EFS/OS |
Note that the cycle begins on day 0.
Preceding treatment
Chemotherapy
- Carboplatin (Paraplatin) 175 mg/m2 IV once per day on days 0, 7, 14, 21, 42, 49, 56, 63
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63
10-week course
Subsequent treatment
- CV maintenance
Regimen variant #2, 550/1.5 (uncapped vincristine)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gnekow et al. 2017 (SIOP-LCG 2004) | 2004-2012 | Phase 3 (C) | VCE | Did not meet primary endpoint of PFS |
Preceding treatment
Chemotherapy
- Carboplatin (Paraplatin) 550 mg/m2 IV over 60 minutes once on day 1
- Vincristine (Oncovin) as follows:
- Cycles 1 to 4: 1.5 mg/m2 IV once per day on days 1, 8, 15
- Cycles 5 to 7: 1.5 mg/m2 IV once on day 1
21-day cycle for 4 cycles, then 28-day cycle for 3 cycles
Subsequent treatment
- VC consolidation
References
- Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. link to original article contains verified protocol PubMed
- COG A9952: Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. link to original article link to PMC article contains verified protocol PubMed NCT00002944
- SIOP-LGG 2004: Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. link to original article link to PMC article contains verified protocol PubMed
Recurrent or progressive, non-curative therapy
Cisplatin & Etoposide (EP)
back to top |
Regimen
Study | Evidence |
---|---|
Massimino et al. 2010 | Non-randomized |
Note: In children less than 1 year old or less than 10 kg, "doses were adjusted to their weight"--reference does not say exactly how doses are adjusted.
Chemotherapy
- Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3, given first
- Etoposide (Vepesid) 100 mg/m2 IV over 30 minutes once per day on days 1 to 3, given second
Supportive medications
- Hydration for 2 hours before chemotherapy, and for 2 hours after chemotherapy
28-day cycle for 4 cycles, then 35-day cycle for 3 cycles, then 42-day cycle for 3 cycles
References
- Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010 Oct;100(1):65-71. Epub 2010 Feb 12. link to original article contains verified protocol PubMed
Temozolomide monotherapy
back to top |
Regimen variant #1
Study | Evidence |
---|---|
Nicholson et al. 2007 | Non-randomized |
Note: This dosing is for patients who previously received craniospinal irradiation (CSI).
Chemotherapy
- Temozolomide (Temodar) 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for 11 cycles
Regimen variant #2
Study | Years of enrollment | Evidence |
---|---|---|
Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
28-day cycle for 11 cycles
References
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article contains verified protocol PubMed